Tonix Pharmaceuticals Holding Corp. - FORM 10-K - EX-32.01 - CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - March 15, 2021

Attached files

file filename
EX-31.02 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - Tonix Pharmaceuticals Holding Corp.ex31-02.htm
10-K - ANNUAL REPORT - Tonix Pharmaceuticals Holding Corp.tnxp-10k_123120.htm
EX-31.01 - CRERTIFICATION OF CHIEF EXECUTIVE OFFICER - Tonix Pharmaceuticals Holding Corp.ex31-01.htm
EX-23.01 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Tonix Pharmaceuticals Holding Corp.ex23-1.htm
EX-21.01 - SUBSIDIARIES OF THE COMPANY - Tonix Pharmaceuticals Holding Corp.ex21-1.htm
EX-10.28 - PURCHASE AND SALE AGREEMENT - Tonix Pharmaceuticals Holding Corp.ex10-28.htm
EX-4.06 - DESCRIPTION OF REGISTRANTS SECURITIES - Tonix Pharmaceuticals Holding Corp.ex4-06.htm

 

Tonix Pharmaceuticals, Inc. 10-K

 

Exhibit 32.01

 

 

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER 

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Seth Lederman, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

 

  By: /s/ SETH LEDERMAN
Date: March 15, 2021 Name: Seth Lederman
  Title: Chief Executive Officer

 

I, Bradley Saenger, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Tonix Pharmaceuticals Holding Corp. on Form 10-K for the fiscal year ended December 31, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in this Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Tonix Pharmaceuticals Holding Corp.

 

  By: /s/ BRADLEY SAENGER
Date: March 15, 2021 Name: Bradley Saenger
  Title: Chief Financial Officer

  

 

Tonix Pharmaceuticals Holding Corp. Reports